Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.
Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.
Tezspire's 2021 approval in severe asthma represents a rapidly growing biologic market opportunity of over $7.5 billion. Early preclinical and clinical data for verekitug indicate a potential for ...
More than 50% of patients with severe asthma have high eosinophil levels, making them candidates for biologic therapies like Nucala and other drugs like AstraZeneca’s Fasenra (benralizumab ...
A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy. In this issue, we unpack Ozempic’s rise ...
A common inhaler drug used to treat tens of thousands of British asthma sufferers has been linked to a rare and potentially fatal hormone condition in children. New research, funded by the ...
The study that Community Health Center patients, like Cridele, have been participating in seeks to alleviate the strain on rural patients by testing their lung performance at home, with a mobile ...